Home › Companies › ADCT

ADC Therapeutics

ADCT Lead: Approved ★ Read the deep dive → 1 Biotech Distilled article ↓

Oncology Protein

Most recent annual filing: 2026-03-10

Pipeline (5 active programs)

ZYNLONTA

loncastuximab tesirine-lpyl

Protein Target: CD19

Diffuse Large B-Cell Lymphoma Approved intravenous
Marginal Zone Lymphoma Phase 2 intravenous
Follicular Lymphoma Phase 2 intravenous
Pediatric B-Cell Non-Hodgkin Lymphoma Phase 2 intravenous

ADCT-241

Protein Target: PSMA

Prostate Cancer Preclinical intravenous

Biotech Distilled coverage (1)

2026-07-10 ADC Therapeutics (ADCT) — Scientific Deep Dive for ZYNLONTA and the CD19 ADC Pipeline

Articles open on Substack. Some deep dives are subscriber-only.